HBIO · Harvard Bioscience, Inc.

Summary

Harvard Bioscience, Inc. furnished its corporate investor presentation dated March 2026 under Item 7.01 Regulation FD Disclosure, highlighting FY25 financial results including $87 million revenue, 58% adjusted gross margin, and $8 million adjusted EBITDA, recent leadership changes, debt refinancing, manufacturing consolidation, and FY26 growth guidance. This provides investors with strategic updates and financial outlook focused on translational science tools.

Key takeaways

• FY25 revenue of $87 million
• FY25 adjusted gross margin of 58%
• FY25 adjusted EBITDA of $8 million
• FY26 revenue growth guidance of 2-4%
• Debt maturity extended to 2029 generating $3 million annual cash savings; BroadOak invested $7.5 million in convertible notes
• John Duke appointed CEO effective July 2025; Mark Frost permanent CFO in March 2026
• Phased closure of Holliston, MA plant expected to deliver $3 million adjusted EBITDA improvement in 2027